DTC Advertising Measurement: A KPI Ladder From Exposure to Therapy
A KPI ladder for DTC pharma measurement: reach, attention, engagement, doctor conversations, starts, and persistence, and what each proves.
The short answer
DTC advertising measurement works best as a ladder: reach on the intended audience, attention and completion, engagement such as site visits and tools used, conversation signals such as doctor discussion guides and appointment requests, new patient starts, and persistence on therapy. Lower rungs come quickly but prove little; upper rungs prove more but need privacy-safe outcome studies with control groups. Report all rungs, and make budget decisions on the highest one you can measure credibly.
DTC reports often lead with impressions and clicks because they are available daily. Prescriptions arrive months later through separate studies. The KPI ladder connects them so each number has a clear job.
The ladder
| Rung | KPI | What it proves | Speed |
|---|---|---|---|
| 1. Reach | Unique households or people reached in the intended audience | The right people could have seen it | Days |
| 2. Attention | Video completion, viewability, attention metrics | They likely saw it | Days |
| 3. Engagement | Site visits, time on site, tool use, searches | Some were interested | Days to weeks |
| 4. Conversation | Discussion guide downloads, appointment requests, savings card sign-ups | Some planned action | Weeks |
| 5. Starts | New patients starting therapy, from privacy-safe data | Behavior changed | Months |
| 6. Persistence | Patients still on therapy over time | Value delivered | Months |
Using each rung well
Reach
Measure against a defined audience, not total impressions. For TV and CTV, use deduplicated household reach. See deduplicated reach.
Attention
Completion and viewability are basic quality checks. Attention metrics vary by vendor; use them to compare placements, not as outcomes.
Engagement
Useful for creative and channel optimization. Be careful: site visits can come from people outside the audience, and many DTC effects happen without a visit.
Conversation
The best near-term signal. Discussion guides, symptom checkers, and savings sign-ups show intent to act.
Starts and persistence
Measured through outcome studies that match exposure to de-identified prescription data, compared with a control group. See choosing a DTC measurement platform.
Avoiding common traps
- Clicks as the headline. CTV and TV impact rarely shows up in clicks.
- Attributed starts presented as incremental. See attributed vs. incremental.
- Optimizing to the wrong rung. Optimizing for site visits can shift spend to cheap clicks from the wrong audience.
Setting up measurement before launch
- Define the audience and how reach will be measured.
- Choose an outcome partner and agree the control design.
- Validate tags and data flows. See measurement tag validation.
- Decide which rung drives weekly optimization and which drives budget decisions.
A monthly DTC report
- Reach and frequency against plan.
- Attention and quality by channel.
- Engagement and conversation signals by channel and creative.
- Outcome study status and latest results with confidence intervals.
The pharma programmatic measurement framework shows how these connect for HCP and DTC together.
Practical takeaway
Look at your current DTC dashboard and label each metric with its rung. If nothing sits on rungs 4 to 6, set up a conversation signal and an outcome study before the next budget cycle.
Frequently asked questions
What KPIs should DTC pharma campaigns use?
Reach on the intended audience, completion or attention, site engagement, conversation signals, new patient starts, and persistence, with outcome measures from privacy-safe studies.
Can DTC campaigns be measured to prescriptions?
Yes, through de-identified matching of exposure to prescription data by measurement partners, compared with a control group.
What is the most misleading DTC metric?
Click-through rate. Most DTC impact happens without a click, especially on TV and CTV.
Sources
- Veeva, Crossix
- HHS, Guidance Regarding Methods for De-identification of PHI
- Media Rating Council, Standards and Guidelines
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.